دورية أكاديمية
أعرض في EDS

Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer.

التفاصيل البيبلوغرافية
العنوان: Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer.
المؤلفون: van Riel LAMJG; Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Geboers B; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Prostate Cancer Research Centre, Sydney, NSW, Australia., Kabaktepe E; Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Blazevski A; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Prostate Cancer Research Centre, Sydney, NSW, Australia., Reesink DJ; Department of Urology, St. Antonius Hospital, Nieuwegein, The Netherlands., Stijns P; St. Vincent's Prostate Cancer Research Centre, Sydney, NSW, Australia., Stricker PD; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; Department of Urology, St. Antonius Hospital, Nieuwegein, The Netherlands., Casanova J; Department of Urology, Instituto Valenciano de Oncologia, València, Spain., Dominguez-Escrig JL; Department of Urology, Instituto Valenciano de Oncologia, València, Spain., de Reijke TM; Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Scheltema MJ; Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Prostate Cancer Research Centre, Sydney, NSW, Australia., Oddens JR; Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
المصدر: BJU international [BJU Int] 2022 Nov; Vol. 130 (5), pp. 611-618. Date of Electronic Publication: 2022 May 13.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-410X (Electronic) Linking ISSN: 14644096 NLM ISO Abbreviation: BJU Int Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford, UK : Blackwell Science, c1999-
مواضيع طبية MeSH: Erectile Dysfunction*/etiology , Prostatic Neoplasms*/surgery , Prostatic Neoplasms*/pathology, Male ; Humans ; Middle Aged ; Prostate-Specific Antigen ; Retrospective Studies ; Quality of Life ; Neoplasm Recurrence, Local/therapy ; Treatment Outcome ; Prostatectomy/adverse effects ; Prostatectomy/methods ; Salvage Therapy/methods ; Electroporation/methods
مستخلص: Objective: To evaluate: (i) safety, (ii) feasibility, and medium-term (iii) oncological and (iv) functional outcomes of salvage radical prostatectomy (sRP) for recurrent localised prostate cancer (PCa) following initial focal therapy using irreversible electroporation (IRE).
Patients and Methods: An international, multicentre and retrospective analysis of prospectively collected data of patients that underwent sRP for recurrent localised PCa after initial primary IRE treatment. Data were reported on (i) surgical complications, (ii) feasibility of sRP reported by surgeons, (iii) time interval between IRE and sRP and pathology results, and (iv) urinary continence, erectile function, and quality of life.
Results: In four participating centres, a total of 39 patients with a median (interquartile range [IQR]) age 64 (60-67) years were identified. No serious adverse events occurred during or following sRP and surgery was deemed feasible without difficulties. The median (IQR) time to recurrence following IRE was 14.3 (9.1-38.8) months. Pathology results showed localised disease in 21 patients (53.8%) and locally-advanced disease in 18 (46.2%). Positive surgical margins (PSMs) were observed in 10 patients (25.6%), of which six (15.4%) had significant PSMs. A persistent detectable prostate-specific antigen level was found in one case after sRP, caused by metastatic disease. One patient had a biochemical recurrence 6 months after sRP. These two cases, together with a PSM case, required additional therapy after sRP. After a median (IQR) follow-up of 17.7 (11.8-26.4) months, urinary continence and erectile function were preserved in 34 (94.4%) and 18 patients (52.9%), respectively, while quality of life remained stable.
Conclusions: Salvage RP is safe and feasible for patients with recurrent localised PCa following initial IRE treatment. The medium-term oncological and functional outcomes are similar to primary RP. Strict patient selection for focal therapy and standardised follow-up is needed as some patients developed high-grade disease.
(© 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.)
التعليقات: Comment in: J Urol. 2023 May;209(5):1010-1011. (PMID: 37026645)
References: Eur Urol Focus. 2019 Jul;5(4):585-591. (PMID: 29102671)
Eur Urol. 2019 Jul;76(1):27-30. (PMID: 30904357)
Urology. 2012 Jul;80(1):130-3. (PMID: 22626582)
Eur Urol Oncol. 2020 Jun;3(3):283-290. (PMID: 31103721)
J Endourol. 2018 Sep 12;32(9):797-804. (PMID: 29790383)
Ann Surg. 2004 Aug;240(2):205-13. (PMID: 15273542)
J Vasc Interv Radiol. 2011 May;22(5):611-21. (PMID: 21439847)
Eur Urol. 2019 Jul;76(1):98-105. (PMID: 30638633)
J Urol. 2018 Apr;199(4):983-989. (PMID: 29107031)
J Urol. 2017 Nov;198(5):1069-1076. (PMID: 28551444)
BJU Int. 2020 Apr;125(4):525-530. (PMID: 31863617)
World J Urol. 2016 May;34(5):657-64. (PMID: 26296371)
World J Urol. 2015 Oct;33(10):1503-9. (PMID: 25559111)
Eur Urol. 2014 Feb;65(2):303-13. (PMID: 23932439)
Radiology. 2020 May;295(2):254-272. (PMID: 32208094)
J Robot Surg. 2017 Jun;11(2):217-221. (PMID: 27995543)
Eur Urol. 2018 Oct;74(4):422-429. (PMID: 29960750)
BJU Int. 2020 Jan;125(1):103-111. (PMID: 31430422)
World J Urol. 2019 Oct;37(10):2147-2153. (PMID: 30671638)
World J Urol. 2019 Aug;37(8):1499-1505. (PMID: 30006908)
Eur Urol. 2021 Feb;79(2):243-262. (PMID: 33172724)
Curr Opin Oncol. 2019 May;31(3):200-206. (PMID: 30865133)
J Urol. 2017 Aug;198(2):335-344. (PMID: 28322857)
J Urol. 2005 May;173(5):1701-5. (PMID: 15821561)
World J Urol. 2019 Aug;37(8):1517-1534. (PMID: 30710157)
J Urol. 2011 Mar;185(3):862-8. (PMID: 21239003)
Eur Urol. 2014 Jun;65(6):1078-83. (PMID: 24444476)
فهرسة مساهمة: Keywords: #PCSM; #ProstateCancer; #uroonc; focal therapy; irreversible electroporation; prostate cancer; radical prostatectomy; recurrence; salvage treatment
المشرفين على المادة: EC 3.4.21.77 (Prostate-Specific Antigen)
تواريخ الأحداث: Date Created: 20220427 Date Completed: 20221021 Latest Revision: 20230421
رمز التحديث: 20230421
مُعرف محوري في PubMed: PMC9790506
DOI: 10.1111/bju.15759
PMID: 35474600
قاعدة البيانات: MEDLINE
الوصف
تدمد:1464-410X
DOI:10.1111/bju.15759